Christopher Ritchlin, ACR 2020 – Results from the DISCOVER-1 Phase 3 Trial
We were delighted to speak to Christopher Ritchlin (University of Rochester, Henrietta, NY, USA) about the one year results from the DISCOVER-1 Phase 3 trial of guselkumab in active psoriatic arthritis (Clinical Trial Identification: NCT03162796). The abstract ‘Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced.’ (ABSTRACT NUMBER: 1344) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What are the major unmet needs in the treatment of patients with active psoriatic arthritis? (0:16)
- What is guselkumab and what is its mechanism of action? (1:39)
- Could you tell us a little about the aims and design of the Phase 3 clinical study you are presenting? (2:56)
- What were the efficacy and safety findings of this study? (4:43)
- What are the implications of these findings for clinical practice? (5:31)
Disclosures: Consultant: Janssen, Abbvie, Amgen, UCB, Sanofi, Novartis, Lilly, Gilead
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis
In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial involvement in psoriatic arthritis. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, […]
Laure Gossec, ACR 2022: Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices
The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing efficacy of guselkumab by multi-domain composite indices. This information is brought to you by Touch […]
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!